Beyond Eosinophil Depletion: Toward Multidimensional Remission in Eosinophilic Gastritis and Duodenitis.
- 1Internal Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt.
Abstract
Eosinophilic gastritis (EoG) and eosinophilic duodenitis (EoD) are chronic, immune-mediated gastrointestinal disorders in which tissue eosinophil density is both an accessible biomarker and a common trial endpoint. Recent targeted studies have shown trial-level divergence between objective endpoints and patient-reported outcomes. This narrative review examines mechanisms, measurement tools, conventional treatment, and biologic studies published or registered through October 2026. In a 26-patient benralizumab trial, histologic remission occurred in 77% of treated patients and 8% of placebo recipients, yet symptom and endoscopic changes were not statistically different. In the DEGAS trial, dupilumab improved histology and endoscopy at 12 weeks, while the symptom change did not differ significantly from placebo. Two Phase 3 lirentelimab trials with registry-posted results met histologic endpoints without significant symptom benefit. Paired individual data are needed to establish within-person discordance. These findings do not make eosinophils unimportant. They show that target engagement, biological disease control, patient status, treatment success, and durability answer different questions. We propose a provisional framework that separates biological disease activity, structural damage, and patient status; treats burden and safety as modifiers of treatment success; and applies duration as a temporal qualifier. The framework favors domain-specific reporting and named discordance states over a single remission score. Patchy disease, variable microscopic field geometry, shallow mucosal sampling, nonspecific symptoms, and limited EoD-specific validation remain important constraints. Patient-informed international consensus and prospective longitudinal testing are needed before the proposed states can guide routine care.
Related
- Beyond eosinophil depletion: long-term clinical trajectory and durability of response to benralizumab in patients with severe eosinophilic asthma and CRSwNP: an 18-month real-world study (the BANDOR study)
- Eosinophil Peroxidase Activity is a Reliable and Resilient Biomarker for Eosinophilic Chronic Rhinosinusitis
- Achieving clinical and histologic remission with tezepelumab in an adolescent with refractory eosinophilic gastrointestinal disease: A case report
- Clinical remission and associated factors in severe eosinophilic asthma patients treated with benralizumab: a real-world study
- Multidimensional nutritional assessment in Crohn’s disease: Cross-sectional comparison of active disease and remission
BibTeX
@article{salman2026beyond,
title = {{Beyond Eosinophil Depletion: Toward Multidimensional Remission in Eosinophilic Gastritis and Duodenitis.}},
author = {Ahmed Salman},
journal = {Clinical and experimental gastroenterology},
year = {2026},
month = oct,
doi = {10.2147/ceg.s652305},
url = {https://europepmc.org/article/MED/42928781},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Beyond Eosinophil Depletion: Toward Multidimensional Remission in Eosinophilic Gastritis and Duodenitis.
AU - Ahmed Salman
PY - 2026
DA - 2026/10/21
JO - Clinical and experimental gastroenterology
DO - 10.2147/ceg.s652305
UR - https://europepmc.org/article/MED/42928781
AB - Eosinophilic gastritis (EoG) and eosinophilic duodenitis (EoD) are chronic, immune-mediated gastrointestinal disorders in which tissue eosinophil density is both an accessible biomarker and a common trial endpoint. Recent targeted studies have shown trial-level divergence between objective endpoints and patient-reported outcomes. This narrative review examines mechanisms, measurement tools, conventional treatment, and biologic studies published or registered through October 2026. In a 26-patient benralizumab trial, histologic remission occurred in 77% of treated patients and 8% of placebo recipients, yet symptom and endoscopic changes were not statistically different. In the DEGAS trial, dupilumab improved histology and endoscopy at 12 weeks, while the symptom change did not differ significantly from placebo. Two Phase 3 lirentelimab trials with registry-posted results met histologic endpoints without significant symptom benefit. Paired individual data are needed to establish within-person discordance. These findings do not make eosinophils unimportant. They show that target engagement, biological disease control, patient status, treatment success, and durability answer different questions. We propose a provisional framework that separates biological disease activity, structural damage, and patient status; treats burden and safety as modifiers of treatment success; and applies duration as a temporal qualifier. The framework favors domain-specific reporting and named discordance states over a single remission score. Patchy disease, variable microscopic field geometry, shallow mucosal sampling, nonspecific symptoms, and limited EoD-specific validation remain important constraints. Patient-informed international consensus and prospective longitudinal testing are needed before the proposed states can guide routine care.
SN - 1178-7023
ER -